Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

By Robert A. Bonomo, D. Szabo. Clinical Infectious Diseases, 2006

772 citations recorded by the source corpus.

Subfields: Molecular Biology, Molecular Medicine, Pollution

View Paper: https://www.semanticscholar.org/paper/c46dec1c9be922790066aea53e457baf9883b063

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. L. Poirel
2. P. Nordmann
3. G. Meletis
4. Lian-zhu Zhang
5. Jian Li
6. Jasmine Lee
7. L. Rice
8. David L. Paterson

In Molecular Medicine

1. P. Nordmann
2. L. Poirel
3. G. Meletis
4. S. Cosgrove
5. David L. Paterson
6. A. Potron
7. C. Giske
8. Jian Li

In Pollution

1. P. Nordmann
2. L. Poirel
3. C. Giske
4. G. Meletis
5. L. Maragakis
6. F. Codjoe
7. E. Donkor

Citations in the corpus

• Carbapenem resistance: overview of the problem and future perspectives (2016, background): “OprD for example, is an outer membrane porin of Pseudomonas aeruginosa through which carbapenems enter its periplasmic space where PBPs are located [Bonomo and Szabo, 2006].”
• Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. (2008, background): “MBLs pose a significant threat because they are often located on mobile genetic elements easily transferred among bacteria [63, 67].”
• Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. (2012, background): “) require special mention; these organisms can be resistant to all currently available antimicrobial agents or remain susceptible only to older, potentially more toxic agents such as the polymyxins, leaving limited and suboptimal options for treatment [5–7].”
• Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. (2015, background): “This ampC gene is associated with a LysR-type regulatory gene with which some -lactam molecules may interact, leading to overexpression of this ampC gene [227].”
• Combination Therapy for Treatment of Infections with Gram-Negative Bacteria (2012, background): “Although the need for definitive combination therapy is questionable, delays in initiating appropriate antimicrobial therapy for pseudomonal infections (which often consists of combination therapy) have been associated with higher mortality (27, 117, 123, 124, 157, 165, 166).”
• Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli (2007, background): “of the world (10), mainly due to carbapenemases and, possibly, other mechanisms, such as alterations of outer membrane proteins (6).”
• Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. (2007, background): “– 5 A major challenge has arisen, however, regarding the treatment of infections caused by Gram-negative bacilli, particularly those with high-level intrinsic resistance to many antibiotic classes and extreme ability to acquire resistance, such as Pseudomonas aeruginosa and Acinetobacter baumannii.(”
• ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, neutral): “Similar to other ESKAPE pathogens, an array of resistance determinants including chromosomal Ade efflux pumps, intrinsic ADC cephalosporinase, the OXA-51 β-lactamase and acquired OXA-type carbapenemases have made A. baumannii a formidable clinical challenge 157 .”
• The hierarchy quorum sensing network in Pseudomonas aeruginosa (2014, background): “The infections caused by P. aeruginosa are usually resistant to treatment by multiple antibiotics and can lead to severe and persistent infections (Bonomo and Szabo, 2006; Chernish and Aaron, 2003; Doshi et al., 2011; Tan, 2008).”